{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:24:54Z","timestamp":1765758294613},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.lungcan.2011.02.017","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T20:44:08Z","timestamp":1302813848000},"page":"274-279","source":"Crossref","is-referenced-by-count":22,"title":["Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study"],"prefix":"10.1016","volume":"74","clinical-trial-number":[{"clinical-trial-number":"nct00949910","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David F.","family":"Heigener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico","family":"van Zandwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Mali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Horwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2011.02.017_bib0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2011.02.017_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0015","unstructured":"Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2004 based on November 2006 SEER data submission, posted to the SEER web site, 2007 [accessed August 27 2010]."},{"issue":"13","key":"10.1016\/j.lungcan.2011.02.017_bib0020","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2005.03.045","article-title":"Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature","volume":"23","author":"D\u2019Addario","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0025","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0030","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"9","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0035","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2011.02.017_bib0040","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.lungcan.2011.02.017_bib0045","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2011.02.017_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdi157","article-title":"Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer","volume":"16","author":"Mohamed","year":"2005","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2011.02.017_bib0060","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CLC.2006.s.008","article-title":"Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer","volume":"8","author":"Perez-Soler","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0065","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0070","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2006.05.8073","article-title":"Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"24","author":"Bezjak","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2011.02.017_bib0075","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","article-title":"Erlotinib in advanced non-small-cell lung cancer (NSCLC): efficacy and safety findings of the Global Phase IV TRUST Study","volume":"5","author":"Reck","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2011.02.017_bib0080","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/JTO.0b013e3181e15d55","article-title":"Efficacy and safety of erlotinib in 1242 East\/South-East Asian patients with advanced non-small-cell lung cancer","volume":"5","author":"Mok","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2011.02.017_bib0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2011.02.017_bib0090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl. 7 (S560)","key":"10.1016\/j.lungcan.2011.02.017_bib0095","article-title":"Erlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the phase III TITAN study","volume":"5","author":"Ciuleanu","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"15s","key":"10.1016\/j.lungcan.2011.02.017_bib0100","article-title":"Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial","volume":"28","author":"Vamvakas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.lungcan.2011.02.017_bib0105","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lungcan.2011.02.017_bib0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.molonc.2007.12.001","article-title":"Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib","volume":"1","author":"Clark","year":"2008","journal-title":"Mol Oncol"},{"issue":"9652","key":"10.1016\/j.lungcan.2011.02.017_bib0115","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2011.02.017_bib0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1634\/theoncologist.11-6-655","article-title":"Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection","volume":"11","author":"Ramalingam","year":"2006","journal-title":"Oncologist"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500211001553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500211001553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T01:56:06Z","timestamp":1560131766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500211001553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0169500211001553"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2011.02.017","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}